With the conduct of multiple clinical trials for gastric cancer, programmed death-1 (PD-1)/programmed death ligand-1 (PD-L1) monoclonal antibodies have been approved for first-line treatment of advanced gastric cancer, and the application of immunotherapy in the perioperative period of gastric cancer is also being explored. This evidence concerns the gene CD274 and gastric cancer.